Dyne Therapeutics
93 hedge funds and large institutions have $568M invested in Dyne Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
23.98% more ownership
Funds ownership: 68.77% → 92.75% (+24%)
12% more funds holding
Funds holding: 83 → 93 (+10)
1% less capital invested
Capital invested by funds: $573M → $568M (-$4.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.01M |
| 2 |
BlackRock
New York
|
+$5.95M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.09M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$4.6M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$4.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.41M |
| 3 |
Bank of New York Mellon
New York
|
-$4.07M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.68M |
| 5 |
SG Americas Securities
New York
|
-$1.16M |
DYN Hedge Fund Activity: Q4 2021 in Review
93 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2021, worth a combined $568M — down 0.79% from $573M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DYN positions and 5 closed out — a net gain of 12 holders — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $6.01M. The largest seller was Wellington Management Group, cutting an estimated $10.3M.
- 93 institutional investors held Dyne Therapeutics (DYN) as of Q4 2021, up from 83 in Q3 2021.
- Funds reported $568M of Dyne Therapeutics stock for Q4 2021, down 0.79% quarter-over-quarter.
- 17 funds opened new Dyne Therapeutics positions in Q4 2021 and 5 closed out, a net change of +12 holders.
- The largest Dyne Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $6.01M added.
- The largest Dyne Therapeutics seller in Q4 2021 was Wellington Management Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2021.